UK markets open in 2 hours 25 minutes
  • NIKKEI 225

    26,717.89
    +547.59 (+2.09%)
     
  • HANG SENG

    23,586.97
    -220.03 (-0.92%)
     
  • CRUDE OIL

    87.29
    +0.68 (+0.79%)
     
  • GOLD FUTURES

    1,797.10
    +4.00 (+0.22%)
     
  • DOW

    34,160.78
    -7.31 (-0.02%)
     
  • BTC-GBP

    27,768.99
    +779.87 (+2.89%)
     
  • CMC Crypto 200

    844.69
    +25.18 (+3.07%)
     
  • ^IXIC

    13,352.78
    -189.34 (-1.40%)
     
  • ^FTAS

    4,230.83
    +38.13 (+0.91%)
     

Dermapharm Holding SE raises EBITDA forecast for the full year 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • DMP.F

Dermapharm Holding SE / Key word(s): Change in Forecast
Dermapharm Holding SE raises EBITDA forecast for the full year 2021

16-Dec-2021 / 12:08 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)
No. 596/2014 on market abuse, as amended
(Market Abuse Regulation - MAR)

Dermapharm Holding SE raises EBITDA forecast for the full year 2021

Grünwald, December 16, 2021 - The Management Board of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) analysed the business development in November on the basis of the preliminary figures in its Management Board meeting today and decided to adjust the forecast for the financial year 2021. Accordingly, the Executive Board now expects Group EBITDA1 to grow by 70 to 75 percent compared to the previous year (previously: 50 to 60 percent). In addition, the Executive Board confirms the revenue forecast for the 2021 financial year of 15 to 20 percent growth compared to the same period of the previous year.

1 EBITDA is an alternative performance indicator that is not defined according to international accounting standards. The Company uses these metrics to allow for better comparability of the business over time and within the industry. EBITDA is defined as earnings before interest, taxes, depreciation and amortisation (see Dermapharm page 31, Annual Report 2020).

>End of the Ad hoc announcement<

Contact

Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 - 64186-233
Fax: +49 (0)89 - 64186-165
E-Mail: ir@dermapharm.com

16-Dec-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Dermapharm Holding SE

Lil-Dagover-Ring 7

82031 Grünwald

Germany

Phone:

+49 (0)89 64 86-0

E-mail:

ir@dermapharm.com

Internet:

ir.dermapharm.de

ISIN:

DE000A2GS5D8

WKN:

A2GS5D

Indices:

SDAX

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange

EQS News ID:

1258883


 

End of Announcement

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting